263 results on '"Herzog, Roland W."'
Search Results
2. In memoriam: Kenneth I. Berns, MD, PhD (1938–2024)
3. Kenneth I. Berns, MD, PhD [1938–2024]
4. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
5. Thorough molecular configuration analysis of noncanonical AAV genomes in AAV vector preparations
6. A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR
7. TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
8. Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography
9. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
10. Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration
11. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
12. The Nobel Prize awarded to pioneers of mRNA vaccines
13. Looking to the future of gene therapy for hemophilia A and B
14. Cellular stress and coagulation factor production: when more isn’t necessarily better
15. Potential role for oral tolerance in gene therapy
16. Plant cell-based drug delivery enhances affordability of biologics
17. The Molecular Therapy family of journals continues to lead the field of gene and cell therapy
18. ASGCT 2023—Gene therapy is becoming medicine
19. Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice
20. AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
21. Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism
22. Factor VIII Trafficking to CD4+ T cells Shapes its Immunogenicity and Requires Several Types of Antigen Presenting Cells
23. Distortion of journal impact factors in the era of paper mills
24. Supplementary Tables and Figures from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
25. Data from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
26. Supplementary Legends from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
27. Supplementary Tables and Figures from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
28. Supplementary Legends from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
29. Data from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
30. Innovation and clinical progress in oral tolerance
31. Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice
32. Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice
33. Two gene therapies for hemophilia available: Now what?
34. Adenoviral gene therapy for bladder cancer
35. First hemophilia B gene therapy approved: More than two decades in the making
36. TLR9-Independent CD8T Cell Responses in Hepatic AAV Gene Transfer Through IL-1R1-MyD88 Signaling
37. Adding recombinant AAVs to the cancer therapeutics mix
38. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice
39. Fast and high-throughput LC-MS characterization, and peptide mapping of engineered AAV capsids using LC-MS/MS
40. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma
41. Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy
42. Oral Anti-CD3 and Bioencapsulated FVIII Therapy Exhibit Distinct Mechanisms That Suppress Inhibitor Formation in Hemophilia a
43. Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII
44. Key Role of Kupffer Cells in IL-1 Dependent Activation of CD8+ T Cell Responses to AAV Transgene Product in Liver
45. Immune complications and their management in inherited and acquired bleeding disorders
46. AAV and hepatitis: Cause or coincidence?
47. Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes
48. Molecular Therapy’s growing impact
49. ASGCT 2022 – Bigger than Ever
50. Addressing the big business of fake science
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.